Tsubota Laboratory Incorporated (JP:4890)
:4890
4890 Stock Chart & Stats
¥340.00
¥1.00(0.24%)
At close: 4:00 PM EST
¥340.00
¥1.00(0.24%)
Day’s Range― - ―
52-Week Range¥251.00 - ¥478.00
Previous CloseN/A
Volume43.10K
Average Volume (3M)31.02K
Market Cap
¥7.84B
Enterprise Value¥6.55B
Total Cash (Recent Filing)¥1.47B
Total Debt (Recent Filing)¥85.26M
Price to Earnings (P/E)―
Beta0.18
Next Earnings
May 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.22
Shares Outstanding25,794,300
10 Day Avg. Volume26,720
30 Day Avg. Volume31,016
Financial Highlights & Ratios
PEG Ratio-0.37
Price to Book (P/B)6.35
Price to Sales (P/S)7.43
P/FCF Ratio-30.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthA strong equity base and low leverage provide durable financial flexibility that supports multi-year R&D and commercialization cycles. This capital structure reduces bankruptcy risk, enables partnership investments or licensing deals, and gives management room to fund product rollouts without immediate reliance on dilutive financing.
Improving Margins And Operating EfficiencyHigh gross margins and rising EBIT/EBITDA indicate structurally efficient production and better operating discipline. Sustained margin improvement boosts the company’s ability to convert incremental revenue into operating profit, supporting long-run reinvestment capacity and margin resilience against competitive pressure.
Clear, Diversified Revenue Model Focused On Eye-health IPA business model combining product sales, IP licensing, and partner-funded development provides multiple durable revenue channels. Licensing and collaborations can yield high-margin, recurring or milestone-based cash, while the focused myopia/eye-health niche supports a defendable market position and strategic partner interest.
Bears Say
Negative Operating And Free Cash FlowPersistent negative operating and free cash flow creates a multi-month to multi-year funding challenge for R&D and commercialization. Even with strong equity, continued cash burn risks requiring external financing or partner-dependent funding, which can dilute control or slow strategic initiatives if not remedied.
Volatile ProfitabilityLarge swings in net profitability reduce predictability of earnings and cash available for reinvestment. This volatility complicates long-term planning, makes multi-year guidance less reliable for partners, and increases execution risk for scaling commercial operations despite recent margin improvements.
Very Small Team / Low Internal ScaleAn extremely small employee base constrains internal capacity for manufacturing scale-up, commercial expansion, and simultaneous R&D projects. The company is likely dependent on partners or key individuals, increasing key-person risk and potentially raising outsourcing costs or delaying market penetration as staffing is scaled.
Tsubota Laboratory Incorporated News
4890 FAQ
What was Tsubota Laboratory Incorporated’s price range in the past 12 months?
Tsubota Laboratory Incorporated lowest stock price was ¥251.00 and its highest was ¥478.00 in the past 12 months.
What is Tsubota Laboratory Incorporated’s market cap?
Tsubota Laboratory Incorporated’s market cap is ¥7.84B.
When is Tsubota Laboratory Incorporated’s upcoming earnings report date?
Tsubota Laboratory Incorporated’s upcoming earnings report date is May 18, 2026 which is in 47 days.
How were Tsubota Laboratory Incorporated’s earnings last quarter?
Tsubota Laboratory Incorporated released its earnings results on Feb 13, 2026. The company reported -¥7.22 earnings per share for the quarter, missing the consensus estimate of N/A by -¥7.22.
Is Tsubota Laboratory Incorporated overvalued?
According to Wall Street analysts Tsubota Laboratory Incorporated’s price is currently Overvalued.
Does Tsubota Laboratory Incorporated pay dividends?
Tsubota Laboratory Incorporated does not currently pay dividends.
What is Tsubota Laboratory Incorporated’s EPS estimate?
Tsubota Laboratory Incorporated’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tsubota Laboratory Incorporated have?
Tsubota Laboratory Incorporated has 25,794,300 shares outstanding.
What happened to Tsubota Laboratory Incorporated’s price movement after its last earnings report?
Tsubota Laboratory Incorporated reported an EPS of -¥7.22 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.534%.
Which hedge fund is a major shareholder of Tsubota Laboratory Incorporated?
Currently, no hedge funds are holding shares in JP:4890
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Tsubota Laboratory Incorporated
Tsubota Laboratory Incorporated engages in the research and development of pharmaceuticals and medical devices for the treatment of myopia, dry eyes, and presbyopia. The company was incorporated in 2012 and is based in Tokyo, Japan.
Technical Analysis
Sundrug Co
―
Sugi Holdings Co
―
TSURUHA Holdings
―
COSMOS Pharmaceutical Corporation
―
KUSURI NO AOKI HOLDINGS CO.,LTD.
―